Fading responses in the evoked EMG after rocuronium in cats.
This study was performed to evaluate the inhibitory effect on motor nerve terminals by rocuronium using recovery curves of muscle compound action potentials (CAPs) and train-of-four ratios (TOFRs) in anaesthetized cats, and to compare the results with other relaxants reported previously. Recovery curves were derived from the amplitude of the CAP induced in the gastrocnemius muscle by the second of a paired stimulus (test response) to the sciatic nerve and compared with results evoked by the first component (conditioning response). The interval between the paired stimuli was increased stepwise from 7 to 1,000 msec, and the differences in amplitude of the test and conditioning responses were plotted on a graph by relating the changes in paired intervals. The recovery curve after rocuronium was less inhibited than after pancuronium, (100.4 +/- 5.9%, 82.3 +/- 6.7% and 68.5 +/- 6.7% at 60, 100 and 500 msec intervals, compared with 70.3 +/- 3.3%, 59.0 +/- 4.7% and 46.7 +/- 4.3% after pancuronium (P < 0.05). The recovery curves with d-tubocurarine were more depressed than with pancuronium; however, the RC with vecuronium was similar to that of rocuronium. The degree of fade in TOF by rocuronium was also less than those seen with d-tubocurarine and pancuronium. The results obtained suggest that rocuronium has less inhibitory effect on motor nerve terminals than do d-tubocurarine and pancuronium, and has a similar effect to that of vecuronium.
Shiraishi
H
H
Department of Anaesthesiology, Surugadai Nihon University Hospital, Tokyo, Japan.
Suzuki
H
H
Suzuki
T
T
Katsumata
N
N
Ogawa
S
S
D000732:Androstanols / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002038:Bungarotoxins / Q000494:pharmacology; D002415:Cats; D004558:Electric Stimulation; D004576:Electromyography / Q000187:drug effects*; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009132:Muscles / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D009469:Neuromuscular Junction / Q000187:drug effects; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000494:pharmacology*; D010197:Pancuronium / Q000494:pharmacology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects / Q000502:physiology; D000077123:Rocuronium; D012584:Sciatic Nerve / Q000187:drug effects* / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects; D014403:Tubocurarine / Q000494:pharmacology; D014673:Vecuronium Bromide / Q000494:pharmacology
D000732:Androstanols; D002038:Bungarotoxins; D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D010197:Pancuronium; D014403:Tubocurarine; D000077123:Rocuronium